These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37862919)

  • 21. MicroRNAs: master regulators of drug resistance, stemness, and metastasis.
    Raza U; Zhang JD; Sahin O
    J Mol Med (Berl); 2014 Apr; 92(4):321-36. PubMed ID: 24509937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical role of HMGA proteins in cancer cell chemoresistance.
    D'Angelo D; Mussnich P; Arra C; Battista S; Fusco A
    J Mol Med (Berl); 2017 Apr; 95(4):353-360. PubMed ID: 28293697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.
    Torki Z; Ghavi D; Hashemi S; Rahmati Y; Rahmanpour D; Pornour M; Alivand MR
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):771-793. PubMed ID: 34510251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulation of microRNAs in cancer.
    Chen PS; Su JL; Hung MC
    J Biomed Sci; 2012 Oct; 19(1):90. PubMed ID: 23075324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.
    Sharma A
    Nanomedicine (Lond); 2017 Sep; 12(17):2137-2148. PubMed ID: 28805111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.
    Liao R; Lin Y; Zhu L
    Mol Biol Rep; 2018 Dec; 45(6):2913-2923. PubMed ID: 30194558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Smoking and microRNA dysregulation: a cancerous combination.
    Momi N; Kaur S; Rachagani S; Ganti AK; Batra SK
    Trends Mol Med; 2014 Jan; 20(1):36-47. PubMed ID: 24238736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance.
    Massaro C; Safadeh E; Sgueglia G; Stunnenberg HG; Altucci L; Dell'Aversana C
    Cells; 2020 Dec; 10(1):. PubMed ID: 33396628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms.
    Braicu C; Gulei D; Raduly L; Harangus A; Rusu A; Berindan-Neagoe I
    Mol Aspects Med; 2019 Dec; 70():90-105. PubMed ID: 31703947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A spotlight on the interplay of signaling pathways and the role of miRNAs in osteosarcoma pathogenesis and therapeutic resistance.
    Doghish AS; Hegazy M; Ismail A; El-Mahdy HA; Elsakka EGE; Elkhawaga SY; Elkady MA; Yehia AM; Abdelmaksoud NM; Mokhtar MM
    Pathol Res Pract; 2023 May; 245():154442. PubMed ID: 37031532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miRNAs modulate the drug response of tumor cells.
    Wu X; Xiao H
    Sci China C Life Sci; 2009 Sep; 52(9):797-801. PubMed ID: 19802736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNAs and drug resistance in prostate cancers.
    Li F; Mahato RI
    Mol Pharm; 2014 Aug; 11(8):2539-52. PubMed ID: 24742219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noncoding RNAs in Therapeutic Resistance of Cancer.
    Jia L; Yang A
    Adv Exp Med Biol; 2016; 927():265-95. PubMed ID: 27376739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?
    Mirzaei S; Zarrabi A; Hashemi F; Zabolian A; Saleki H; Ranjbar A; Seyed Saleh SH; Bagherian M; Sharifzadeh SO; Hushmandi K; Liskova A; Kubatka P; Makvandi P; Tergaonkar V; Kumar AP; Ashrafizadeh M; Sethi G
    Cancer Lett; 2021 Jul; 509():63-80. PubMed ID: 33838282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types.
    Hummel R; Hussey DJ; Haier J
    Eur J Cancer; 2010 Jan; 46(2):298-311. PubMed ID: 19948396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs in cancer drug resistance: Basic evidence and clinical applications.
    Ghasabi M; Mansoori B; Mohammadi A; Duijf PH; Shomali N; Shirafkan N; Mokhtarzadeh A; Baradaran B
    J Cell Physiol; 2019 Mar; 234(3):2152-2168. PubMed ID: 30146724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNAs in melanoma development and resistance to target therapy.
    Fattore L; Costantini S; Malpicci D; Ruggiero CF; Ascierto PA; Croce CM; Mancini R; Ciliberto G
    Oncotarget; 2017 Mar; 8(13):22262-22278. PubMed ID: 28118616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer.
    Riquelme I; Letelier P; Riffo-Campos AL; Brebi P; Roa JC
    Int J Mol Sci; 2016 Mar; 17(3):424. PubMed ID: 27011182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics.
    Allen KE; Weiss GJ
    Mol Cancer Ther; 2010 Dec; 9(12):3126-36. PubMed ID: 20940321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emerging role of microRNAs in resistance to lung cancer treatments.
    MacDonagh L; Gray SG; Finn SP; Cuffe S; O'Byrne KJ; Barr MP
    Cancer Treat Rev; 2015 Feb; 41(2):160-9. PubMed ID: 25592062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.